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Background: The aim of this study is to evaluate the role of arterial stiffness in pulmonary arterial hyper-
tension (PAH) in systemic lupus erythematosus (SLE) patients and its relationship with antiphospholipid
antibody (aPL).
Methods: Measurement of brachial ankle pulse wave velocity (baPWV), carotid arterial stiffness, and
pulmonary vascular resistance (PVR) was performed in 51 patients with SLE. PAH was diagnosed if the
pulmonary artery systolic pressure was >40mmHg. Information concerning SLE duration, medication,
and serum autoantibodies was recorded. SLE activity was assessed by the SLE disease activity index
(SLEDAI).
Results: aPL was present in 10 patients (20%), and PAH was detected in 6 patients (12%). The prevalence
of Raynaud’s phenomenon, baPWV, positive aPL, and titers of IgG anticardiolipin antibody (aCL) were
increased in SLE with PAH; however, no difference was found in inﬂammatory markers, disease duration,
and SLEDAI compared to SLEwithout PAH. Carotid artery deformation and right ventricular functionwere
reduced in patients with PAH (all p<0.05). Carotid artery circumferential strain (r=0.34, p=0.021), radial
strain (r=−0.30, p=0.045), and baPWV (r=0.46, p=0.001) showed signiﬁcant correlation between IgG
aCL. Univariate andmultiple regression analysis revealed that the only signiﬁcant independent predictors
of the presence of PAH were baPWV, carotid artery stiffness, and IgG aCL.
Conclusion: Arterial stiffness might contribute to the pathogenesis of PAH related to SLE as well as aPLs.
Furthermore, the signiﬁcant association of aPL with arterial stiffness suggests its important role in PAH
with SLE.
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Pulmonary arterial hypertension (PAH) is a serious complication
hat is associatedwith a signiﬁcant risk of death, and survival is sig-
iﬁcantly reduced in systemic lupus erythematosus (SLE) patients
ith PAH compared with those with idiopathic PAH (45% vs. 73%
t 3 years) [1]. Estimates of the prevalence of PAH in SLE vary from
.5 to 43% [2–5]. This wide variability in the reported prevalence
ates reﬂects the differences in the deﬁnitions of PAH, diagnos-
ic methods, population groups studied, and number of patients
nvolved.
The etiology of PAH in SLE patients is not clear, but studies have
hown an imbalance between vasoconstrictors and vasodilators
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in SLE-associated PAH, implying that endothelial dysfunction is a
possible factor in its pathogenesis [6]. A role of inﬂammation in
the development of PAH has also been suggested [7], and levels of
inﬂammatory cells, including macrophages and lymphocytes, are
increased in the plexiform lesions of hypertensive pulmonary ves-
sels [8]. Although a causal relationship between SLE and PAH has
not been established, the various elements of SLE, from vasculitis
and in situ thrombosis to interstitial pulmonary ﬁbrosis, can lead
to endothelial and smooth muscle proliferation and damage of the
pulmonary vasculature resulting in PAH.
In patients with SLE, antiphospholipid antibodies (aPL) are
associated with arterial and venous thrombosis, and aPL accom-
panying SLE may form part of the pathophysiology of PAH [9,10].
They increased the risk of thrombosis and thromboembolism,
and thrombogenic pulmonary vasculopathy has been documented
in many patients with PAH [9,10]. Although some studies have
suggested association of aPL with carotid artery intima-media
thickness [11] and abnormal left ventricular diastolic ﬁlling [12],
its association with arterial stiffness is uncertain. In this study,
served.
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e evaluated the prevalence of PAH in a cohort of SLE and the
ole of arterial stiffness as well as disease-speciﬁc autoimmune or
nﬂammatory markers in SLE–PAH. We hypothesized that if arte-
ial stiffness plays a signiﬁcant role in the pathogenesis in SLE–PAH,
hen the association with levels of aPL and arterial stiffness might
e present.
ethods
tudy population
Fifty-one SLE patients (aged 47.1±14.7 years, 32 women)
rom the outpatient clinic of the rheumatology division who
ere diagnosed according to American College of Rheumato-
ogy criteria [13] were consecutively included. Exclusion criteria
ere smoking (in the last 5 years), diabetes mellitus, hyper-
ension, hypercholesterolemia, renal failure, chronic hepatopathy,
ephrotic syndrome, and hypothyroidism. Interstitial lung disease
as excluded by high-resolution computed tomography, chronic
hromboembolic pulmonary hypertension (CTEPH) was excluded
y ventilation/perfusion lung scanning, and patients with evidence
f congenital heart diseases, signiﬁcant valvular disease, chronic
bstructive pulmonary disease, portal hypertension, immunode-
ciency virus, thyroid disorders, asplenia secondary to surgical
plenectomy, sickle cell disease, thalassemia, chronic myelopro-
iferative disorders, and pregnancy were excluded. The study was
pproved by the Institutional Review Board and informed consent
as obtained from all participants.
chocardiographic examination
All echocardiography examinations were performed on a GE
ivid 7 ultrasound machine (GE Medical System, Horden, Norway)
ith a 2.5MHz transducer. Two-dimensional and M-mode mea-
urements were performed according to the recommendations of
he American Society of Echocardiography. Left ventricular (LV)
nd right ventricular (RV) ejection fractions (EF) were estimated
sing modiﬁed Simpson’s methods. Isovolumic contraction time
ICT), isovolumic relaxation time (IVRT), and ejection time derived
rom tissue Doppler imaging data were obtained, and the index of
ombined systolic and diastolic function [myocardial performance
ndex; MPI = (ICT+ IVRT) divided by ejection time] was calculated.
he RV outﬂow tract (RVOT) time velocity integral (TVIRVOT; in
m) was obtained by positioning the sample volume of the pulsed
ave Doppler at the RVOT. Pulmonary vascular resistance (PVR)
as calculated by the simple index of maximal tricuspid regur-
itation velocity (TR Vmax)/TVIRVOT, which is easy and quick to
btain and can provide important information about the degree of
ulmonary vascular involvement. The Doppler-derived pulmonary
rtery systolic pressure (PASP; in mmHg) was then calculated from
he TR Vmax using the simpliﬁed Bernoulli formula as follows:
ASP=4× (TR Vmax)2 + right atrial pressure. PAH was deﬁned as
PASP of at least 40mmHg. RV function was measured using tri-
uspid annular plane systolic excursion (TAPSE), RV MPI, RV EF,
nd peak systolic strain at the base and mid-free wall side of RV
ssessed by tissue Doppler imaging. We also measured the global
V free wall strain by speckle tracking strain imaging. All echocar-
iographic examinations were performed by a single experienced
perator (KI Cho) and then analyzed off-line with an EchoPAC
imension system (General Electric) by the same operator blinded
o the clinical status of study subjects.easurement of carotid arterial stiffness
We measured deformation parameters of the carotid arterial
all by speckle tracking strain imaging [14]. Circumferential peakdiology 64 (2014) 450–455 451
systolic strain (%)wasmeasured as an average of thewhole circular
region of interest (ROI) giving the respective ‘global’ strain. ‘Global’
values for radial strain could not be calculated due to limitations of
the EchoPAC software and consequently radial peak systolic strain
was only obtained ‘regionally’ from a discrete point (20×20pixels)
located in the far wall of the vessel. During systole, circumferential
strain assumes positive values due to stretching or expansion of
the vessel wall whereas radial strain becomes negative as a result
of compression of the vessel wall. The frame rate for the two-
dimensional strain was 60±15 frames/s, and the ROI was placed
at the adjacent arterial wall if plaque existed. Interobserver and
intraobserver variations for strain were 10% and 12%, respectively.
Measurement of peripheral arterial stiffness
Arterial stiffness was assessed by measuring brachial-ankle
pulse wave velocity (baPWV) using an automatic waveform ana-
lyzer (VP-1000; Colin Co., Komaki, Japan) [15]. The VP-1000
simultaneously records pulse waves, blood pressure (both arms
and ankles), ankle-brachial pressure index (ABI), electrocardio-
gram, andheart sounds, as described elsewhere [16]. Formeasuring
baPWV, pulse waves obtained from the brachial and tibial arteries
were recorded simultaneously, and the transmission time, deﬁned
as the time interval between the initial increase in brachial and
tibial waveforms, was determined. The transmission distance from
the arm to each ankle was calculated according to the body height.
The baPWV was automatically computed as the transmission dis-
tance divided by the transmission time. All participants included in
the present study had a normal ABI (>0.9).
Disease-speciﬁc evaluation
Disease activity was assessed by the SLE disease activity index
(SLEDAI) [17]. All SLE patients and controls fasted for at least 12h
at the beginning of the study before blood tests. Peripheral blood
cell counts were determined using an automated hematology ana-
lyzer (SE-9000; Sysmax, Kobe, Japan). In terms of immunological
parameters, we measured anti-double stranded DNA antibodies
(anti-dsDNA Ab) by enzyme immunoassay (EIA) with the Bio-
Flex DNA ds test (Bioﬂex, Japan), which does not react with
single-strandedDNA(reference: IgG≤4 IU/ml, IgM≤20 IU/ml), and
antinuclear antibody (ANA) and complement concentrations on
an autoanalyzer (ADIVA 1800; Siemens, New York) by turbid
immunometry (reference: C3 50–90mg/dl, C4 10–40mg/dl). The
2 glycoprotein I (GPI)-dependent anti-cardiolipin antibody (aCL)
titersweredeterminedusingEIA (DRVVT;Diluted-Russell, S-Viper-
Venom Test) and deﬁned positive as IgG or IgM anticardiolipin
>12 IU/ml or the presence of lupus anticoagulant. The anti-Ro anti-
body (reference: ≤1.0AI), anti-La antibody (reference: ≤1.0AI),
anti-Smith (Sm) antibody (reference: ≤1.0AI), and antiRNP anti-
body (reference: ≤1.0AI) were also measured by EIA. The plasma
concentrations of high sensitivity C-reactive protein (hsCRP) were
measured using fully automated turbid immunometry (Advia
1800). ANA levels were also determined in controls to exclude the
presence of autoimmune diseases.
Statistical analysis
Statistical analysis was performed with the statistical program
SPSS for Windows version 12.0 (Chicago, IL, USA). Results are
presented as mean± standard deviation (SD) or percentage. Com-
parisons were performed between patients and control groups
using Student’s t-test for quantitative variables and chi-square or
the exact Fisher test for qualitative variables. Comparison between
patients with and without PAH was performed by Mann–Whitney
U test. Correlations between variableswere assessed by calculating
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he correlation coefﬁcientwith Pearson correlation tests. Statistical
igniﬁcance was set as p<0.05.
esults
linical characteristics of patients
Patient characteristics compared with healthy controls are
iven in Table 1. At the time of the study, 46 SLE patients (92%)
ere taking prednisolone, 30 (60%) were taking non-steroidal
nti-inﬂammatory drugs (NSAIDs), and 30 (60%) were taking
ydroxychlorquine. The mean cumulative dose for steroid treat-
ent (prednisolone) was 4513±5404mg. Eight patients (16%)
ad taken immunosuppressantdrugs, includingcyclophosphamide
nd azathioprine. Thirty-nine patients (78%) did not have pro-
einuria, and four patients (8%) had nephrotic range proteinuria.
here were no signiﬁcant differences between SLE patients and
ontrols in terms of age and other parameters that are known to
ffect arterial stiffness (Table 1). However, SLE patients showed sig-
iﬁcantly increased baPWV (1312±281 cm/s vs. 1227±141 cm/s,
able 1
aseline characteristics and parameters of the study population.
SLE patients (n=51)
Age (years) 47.1±14.7
Female, n (%) 32 (62.7%)
BMI (kg/m) 22.1±5.9
Systolic blood pressure (mmHg) 113.7±13.7
Diastolic blood pressure (mmHg) 71.3±10.4
Total cholesterol (mg/dl) 189.3±24.7
Mean IMT (mm) 0.71±0.16
Plaque, n (%) 14 (27.5%)
PASP (mmHg) 29.9±6.78
Mean baPWV (cm/s) 1312±281
Carotid circumferential strain (%) 3.61±1.25
Carotid radial strain (%) −3.74±1.22
ll values are presented as mean± SD.
MI, body mass index; SLE, systemic lupus erythematosus; PASP, pulmonary arterial s
hickness.
able 2
haracteristics of SLE patients with and without pulmonary arterial hypertension.
SLE patients
With PAH (n=6)
Age (years) 49.2±9.2
Disease duration (years) 5.3±4.8
Total cholesterol (mg/dl) 199.7±24.5
Systolic blood pressure (mmHg) 114.5±17.5
Diastolic blood pressure (mmHg) 72.5±11.5
hsCRP (mg/dl) 1.92±3.49
SLEDAI score 5.37±4.84
Raynaud’s phenomenon, n (%) 5 (83%)
Anti-dsDNA IgG (IU/ml) 27.6±55.1
Anti-dsDNA IgM (IU/ml) 27.8±26.0
Positive anti-Sm, n (%) 1 (17%)
Positive anti-Ro, n (%) 3 (50%)
Positive anti-La, n (%) 2 (33%)
C3 (mg/dl) 125.1±26.3
C4 (mg/dl) 23.9±10.0
IgG aCL (IU/ml) 61.0±79.8
IgM aCL (IU/ml) 8.87±6.67
Antiphospholipid antibody, n (%) 5 (83%)
Mean baPWV (cm/s) 1759±357
Carotid IMT (mm) 0.71±0.17
Plaque, n (%) 2/6 (33%)
Carotid circumferential strain (%) 2.34±0.54
Carotid radial strain (%) −2.57±0.74
ll values are presented as mean± SD.
LE, systemic lupus erythematosus; PAH, pulmonary arterial hypertension; hsCRP, high se
ndex; anti-dsDNA Ab, anti-double stranded DNA antibodies; aCL, anti-cardiolipin antibodiology 64 (2014) 450–455
p=0.043), reduced carotid circumferential strain (3.61±1.25% vs.
6.59±1.78%, p<0.001), and reduced radial strain (−3.74±1.22 vs.
−4.98±1.55%, p=0.007) compared with the controls. In addition,
there was a signiﬁcant increase in PASP in SLE patients compared
with controls (29.9±6.78mmHg vs. 12.3±8.0mmHg, p=0.002).
Clinical characteristics of patients according to the presence of
pulmonary arterial hypertension
aPL was present in 10 patients (20%) and PAH was detected in 6
of the 51 SLE patients (12%). To further examine the association of
PAH with clinical parameters or vascular indices, we dichotomized
the SLE patients with and without PAH; the results of this asso-
ciation are presented in Tables 2 and 3. There is no difference
in blood pressure, total cholesterol, hsCRP, disease duration, and
SLEDAIbetweenSLEpatientswithandwithoutPAH.Although there
werenodifferences in anti-dsDNAantibodies and complement lev-
els, IgG aCL titer was signiﬁcantly higher and the parameters of
carotid artery deformation were reduced in patients with PAH (all
p<0.05, Table 2) with signiﬁcant increase in baPWV (1759±357
Controls (n=50) p
50.3±10.1 0.122
29 (58%) 0.841
22.4±4.9 0.683
121.9±10.0 0.082
73.8±7.3 0.124
185.8±28.7 0.452
0.63±0.09 0.043
3 (6%) <0.001
12.3±8.0 0.002
1227±141 0.043
6.23±1.78 <0.001
−4.75±1.55 0.007
ystolic pressure; baPWV, brachial ankle pulse wave velocity; IMT, intima media
p
Without PAH (n=45)
46.8±15.4 0.673
6.0±4.9 0.782
193.6±28.1 0.382
113.6±13.4 0.827
71.1±10.3 0.805
2.40±3.36 0.590
6.29±6.73 0.154
17 (38%) 0.046
31.2±53.9 0.221
27.0±32.1 0.625
10 (2%) 0.723
24 (53%) 0.457
18 (40%) 0.473
99.8±37.8 0.103
23.7±12.3 0.961
6.13±12.6 0.003
5.18±14.1 0.061
5 (11%) 0.001
1322±233 0.029
0.69±0.08 0.679
12/45 (27%) 0.354
3.71±1.17 0.002
−3.90±1.20 0.006
nsitivity C-reactive protein; SLEDAI, systemic lupus erythematosus disease activity
dy; baPWV, brachial ankle pulse wave velocity; IMT, intima media thickness.
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Table 4
Correlation coefﬁcients between arterial stiffness/clinical parameters and PAH
among the SLE group (n=51).
PASP PVR
r p r p
Age −0.113 0.433 −0.239 0.094
Disease duration 0.070 0.630 −0.084 0.562
Mean blood pressure −0.113 0.433 −0.239 0.094
Total cholesterol 0.086 0.164 0.037 0.348
hsCRP −0.084 0.566 −0.142 0.327
IgG aCL titer 0.359 0.029 0.408 0.012
Antiphospholipid antibody 0.487 0.001 0.379 0.009
SLEDAI 0.286 0.074 0.139 0.328
Raynaud’s phenomenon 0.427 0.002 0.368 0.009
baPWV 0.264 0.064 0.621 <0.001
Circumferential strain −0.473 0.001 −0.236 0.100
Radial strain 0.456 0.001 0.461 0.001
PAH, pulmonary arterial hypertension; SLE, systemic lupus erythematosus; PASP,
pulmonary arterial systolic pressure; PVR, pulmonary vascular resistance; hsCRP,
high sensitivity C-reactive protein; aCL, anti-cardiolipin antibody; SLEDAI, systemicJ.H. Lee, K. Im Cho / Journal
s. 1322±233,p=0.029). Raynaud’sphenomenonandaPLaremore
revalent in patientswith PAH (all p<0.05, Table 2). Although there
ere no differences in LV function, parameters of RV function such
s global/regional RV strain andTAPSEwere signiﬁcantly decreased
n patients with SLE with PAH compared with SLE patients without
AH (all p<0.05, Table 3).
orrelation of vascular indices with clinical features in SLE
atients
Traditional clinical factors affecting arterial stiffness, such as
ge, blood pressure, total cholesterol, and inﬂammatory mark-
rs (hsCRP), and parameters of disease activity (SLEDAI) showed
o correlation with PASP and PVR, but the parameters of arterial
tiffness (carotid artery deformation and baPWV), Raynaud’s phe-
omenon, aPL and IgG aCL titer showed signiﬁcant associationwith
ASP and PVR (all p<0.05, Table 4). Carotid artery circumferential
train (r=0.34, p=0.021), radial strain (r=−0.30, p=0.045), and
aPWV (r=0.46, p=0.001) showed signiﬁcant correlation between
gG aCL titers.Whenmultiple regression analysiswas performed to
djust for any potential confounding inﬂuence of age, cholesterol,
uration of disease, and the clinical variables of SLE, the signiﬁcant
ndependent predictors of the presence of PAH were carotid cir-
umferential strain (adjustedodds ratio (OR), 1.043, 95%conﬁdence
nterval (CI), 1.002–1.084), radial strain (adjusted OR, 1.126, 95%
I, 1.079–1.175), baPWV (adjusted OR, 1.075, 95% CI, 1.014–1.136),
nd IgG aCL titer (adjusted OR, 1.231, 95% CI, 1.086–1.375) after
djustment for traditional risk factors (Table 5).
iscussion
The present study showed that PAH was detected in 12% of
LE patients and signiﬁcantly higher values of PASP were detected
n SLE patients in comparison to controls. Moreover, a reduction
n elastic properties of carotid artery wall and increased arterial
tiffness was more prevalent in SLE patients, especially those with
AH. Arterial stiffness and aPL (particularly IgG aCL) proved to be
able 3
chocardiographic parameters of SLE patients with and without pulmonary arterial
ypertension.
SLE patients p
With PAH (n=6) Without PAH (n=45)
LVEDD (mm) 45.5 ± 3.47 45.6 ± 4.76 0.827
LV EF (%) 65.5 ± 7.06 67.1 ± 5.51 0.570
LA diameter (mm) 31.2 ± 7.64 33.1 ± 4.93 0.570
CO (l/min) 4.48 ± 0.78 4.45 ± 1.16 0.631
PVR (dyn/s/cm5) 2.47 ± 0.29 1.20 ± 0.37 <0.001
Mean PAP (mmHg) 24.0 ± 6.89 8.03 ± 3.80 <0.001
E (cm/s) 74.0 ± 10.5 66.8 ± 16.2 0.119
A (cm/s) 62.3 ± 13.7 63.8 ± 18.2 0.942
E′ (cm/s) 6.60 ± 2.69 7.85 ± 2.12 0.223
E/E′ 12.2 ± 3.38 8.92 ± 2.38 0.025
LV MPI 0.38 ± 0.14 0.35 ± 0.15 0.673
RV MPI 0.58 ± 0.18 0.39 ± 0.18 0.016
RA diameter (mm) 31.3 ± 3.06 25.0 ± 4.17 0.001
RV FAC (%) 33.4 ± 13.2 40.3 ± 9.35 0.161
RV EF (%) 48.6 ± 8.67 55.1 ± 11.6 0.165
TAPSE (mm) 20.1 ± 2 24.3 ± 3.4 <0.001
Global RV strain (%) −16.2 ± 2.32 −21.3 ± 3.35 0.002
Basal RV strain (%) −15.5 ± 0.80 −19.2 ± 3.53 0.009
Mid RV strain (%) −16.9 ± 1.21 −26.7 ± 5.74 <0.001
V, left ventricular; EDD, end-diastolic dimension; EF, ejection fraction; LA, left
trium; CO, cardiac output; PVR, pulmonary vascular resistance, PAP, pulmonary
rterial pressure; E, transmitral peak early diastolic velocity; A, transmitral peak late
iastolic velocity; E′ , early diastolic mitral annular velocity; MPI, myocardial perfor-
ance index; FAC, fractional area; RV, right ventricular; TAPSE, tricuspid annular
lane systolic excursion.lupus erythematosus disease activity index; baPWV, brachial ankle pulse wave
velocity.
signiﬁcant predictors of PAH in SLE, suggesting that thrombosis
and endothelial dysfunction may have an important role in the
pathogenesis of PAH in SLE.
Increased PVRmay result frommultiplemechanisms in patients
with SLE-associated PAH, including hypoxia due to lung dis-
ease (hypoxic vasoconstriction), pulmonary venous hypertension
due to left heart disease, aPL predisposing to in situ throm-
bosis or acute/chronic thromboemboli, high output state from
non-cirrhotic portal hypertension, and pulmonary venoocclusive
disease/pulmonary capillary hemangiomatosis [18]. In addition,
studies have shown an imbalance between vasoconstrictors and
vasodilators in SLE–PAH, with higher levels of endothelin-1 [19]
and thromboxane A2 and inhibition of prostacyclin production by
endothelial cells. Regarding this, Raynaud’s phenomenon may be
associated with PAH [20], and our study showed a similar result. In
this study, for the ﬁrst time, we estimated the elastic properties of
the carotid arterial wall based on strain parameters determined by
speckle tracking imaging in SLE patients. We previously showed
that speckle tracking imaging is a comparative method for the
assessmentof elasticpropertiesof carotidartery [14], because these
parameters are useful for quantiﬁcation of radial (or axial) and
circumferential thickening of the carotid arterial wall. Consider-
ing the tubular shape of the common carotid artery, measuring
global circumferential strain would potentially be superior to tis-
sue Doppler imaging [21]. As strain values of the carotid arterial
wall may be decreased at the early stage of atherosclerosis, this
method may be useful in screening to identify or exclude patients
with atherosclerosis. This is supported by the fact that arterial stiff-
ness is caused by changes in wall components that increase the
collagen to elastin ratio and rearrangement of the wall materi-
als, resulting in loss of distensibility of the vessel wall [22]. This
study conﬁrmed that a decrease in the elastic properties of the
carotid artery wall as well as increase in baPWV was more preva-
lent in SLE patients, especially thosewith PAH.We found that lower
strain values and increased baPWV were associated with PASP and
PVR. Because the possible role of arterial stiffness in determining
increased PVR has been poorly investigated, the present data may
add further knowledge on the pathogenesis of PAH in SLE. In addi-
tion to measuring the elastic properties of the carotid artery, this
study demonstrates that global and regional systolic function of
the RV can be quantiﬁed simultaneously by the speckle tracking
method, and patients with PAH showed signiﬁcantly reduced RV
function, represented by higher RV myocardial performance index
and reduced RV strain. Because RV function mainly determines
454 J.H. Lee, K. Im Cho / Journal of Cardiology 64 (2014) 450–455
Table 5
Binary logistic regression analysis of parameters of arterial stiffness, clinical parameters, and pulmonary artery hypertension in SLE groups.
OR (95% CI) p Adjusted OR (95% CI) p
Age 1.066 (0.996–1.136) 0.332 1.037 (0.899–1.175) 0.772
Disease duration 1.005 (0.998–1.022) 0.602 1.000 (0.960–1.043) 0.584
Mean blood pressure 1.007 (0.984–1.031) 0.528 0.994 (0.941–1.050) 0.843
Total cholesterol 1.072 (0.956–1.187) 0.231 1.035 (0.986–1.084) 0.989
hsCRP 1.006 (1.000–1.011) 0.058 1.010 (0.988–1.033) 0.563
IgG aCL titer 1.106 (1.076–1.136) <0.001 1.126 (1.079–1.175) 0.001
SLEDAI 0.985 (0.968–1.093) 0.102 0.805 (0.377–1.716) 0.221
baPWV 1.005 (1.002–1.008) 0.003 1.075 (1.014–1.136) 0.002
Circumferential strain 1.096 (1.005–1.187) 0.009 1.043 (1.002–1.084) 0.005
Radial strain 1.106 (1.076–1.136) <0.001 1.126 (1.079–1.175) 0.001
The presence of pulmonary artery hypertension (R2 = 0.319, adjusted R2 = 0.242 in multivariate analysis).
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oth the patients’ functional capacity and survival [23,24], these
dditional ﬁndings suggest the poor prognosis of the SLE with PAH.
Another key mechanism in PAH development involves inﬂam-
atory process such as elevated levels of inﬂammatory protein
25,26] or plaque activation [27]. It appears that PAH in the set-
ing of SLE does not represent one homogenous condition, but
ay reﬂect a ﬁnal common pathway for a few distinct pathologi-
ally based subsets [28]. One such subset may be patients prone
o thromboembolic disease. Features of this subset include the
resence of aPL [29–31], and our data were concordant with the
revious ﬁndings claiming that aPLs were associated with PAH
11,12,30,31]. Pathogenic aPLs activate the endothelial cells,mono-
ytes, and platelets leading to a prothrombotic state. As a result,
LE patients with aPLs are more susceptible to in situ thrombosis
nd thrombotic arteriopathy and should be screened for the CTEPH
r PAH. In our study cohort, two SLE patients (4%) who were ini-
ially suspected of having PAH were excluded because they were
iagnosed as CTEPH. Once they were diagnosed as PAH from our
tudy, we used oral anticoagulants for all patients (n=6), although
AH-speciﬁc treatment was administered (n=3) according to the
ymptoms.
Pulmonary vasculopathy may manifest as non-inﬂammatory
ascular remodeling, associated with anti-ribonucleoprotein [32],
r as an immune-mediated vasculopathy with inﬂammation. Pre-
ious studies showed that these PAH patients have circulating
utoantibodies, including antinuclear antibodies [33], and ele-
ated circulating levels of proinﬂammatory cytokines such as
nterleukin-1 and interleukin-6 [25,26]. However, in our study, cir-
ulating CRP levels were not increased in PAH patients compared
ith controls.
This study has some limitations that should be considered.
he ﬁrst is related to the small number of patients and selection
f the study population. Further study with a larger population
hould be undertaken to overcome this limitation. Second, hemo-
ynamic assessmentwas totally based on an indirectmethod using
chocardiography, although tricuspid regurgitation method using
he Bernoulli’s equation showed a good correlation with cardiac
atheterization data. Third, we assessed SLE activity by SLEDAI, and
id not assess the damage index. Recently, there was an article that
howed SLICC/American College of Rheumatology damage index
ndependently associated with LV diastolic function in patients
ith SLE. It would be useful to verify the correlation between PAH
nd SLE damage index,which reﬂect the inﬂammatory burden [34].
inally, we evaluated hsCRP levels only once, at baseline, and did
ot evaluate the effects of changes in the levels of this marker
ver time. Variation in the levels of inﬂammatory markers over
ime could lead to a false estimation; therefore, follow-up stud-
es that evaluate the effects of changes in inﬂammation have to bensitivity C-reactive protein; aCL, anti-cardiolipin antibody; SLEDAI, systemic lupus
undertaken.Nonetheless, this studyhighlighted the clinical pattern
of SLE–PAH patients and identiﬁed carotid circumferential strain,
radial strain, baPWV, and IgG aCL as leading predictors of PAH
development among patients with SLE. Routine echocardiography
is recommended in SLEpatientswith these independentpredictors.
Conclusions
In summary, our data suggest that SLE accompanied by PAH
is associated with decreased carotid artery strain and increased
baPWV even in the absence of traditional cardiovascular risk fac-
tors. This studyalso showed that thepresenceof PAH inSLEpatients
was related to the presence of aPL (particularly IgG aCL) as well
as increased arterial stiffness. These ﬁndings reinforce the need to
evaluate aPL in SLE patients to identify predictors of PAH. Greater
understanding of the role of aPL and arterial stiffness will facilitate
the development of novel targeted therapies.
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